Clinical efficacy and safety analysis of Senqi Xiaoji Formula combined with karelizumab and apatinib in the treatment of intermediate and advanced hepatocellular carcinoma
Objective:Exploring the clinical efficacy and safety of Shenqi Xiaoji Formula combined with Karelizumab and Apatinib in the treatment of advanced hepatocellular carcinoma.Methods:A total of 74 patients with middle and advanced stage hepatocellular carcinoma of the liver depression and spleen deficiency type were selected and divided into a study group and a control group,with 37 cases in each.The control group was treated with the"Camrelizumab and Apatinib"regimen,while the study group was additionally treated with the Shenqi Xiaoji Formula on the basis of the control group's treatment.The therapeutic effects of the two groups were analyzed in terms of TCM efficacy indicators,clinical efficacy,liver function,alpha-fetoprotein(AFP)levels,Karnofsky Performance Status(KPS),adverse reaction incidence,and overall survival time.Results:After 2 months of treatment,the clinical efficacy,overall survival,and KPS score of the study group were better than those of the control group(P＜0.05).The liver function,traditional Chinese medicine efficacy indicators,and AFP of the two groups of patients improved after treatment,with the study group showing more significant improvement(P＜0.05),and the incidence of adverse reactions in the study group was significantly lower than that in the control group(P＜0.05).Conclusion:The combination of Shenqi Xiaoji Formula,Karelizumab,and Apatinib has a clear clinical efficacy in the treatment of advanced hepatocellular carcinoma patients with liver depression and spleen deficiency type.It can prolong the life cycle and improve quality of life,and is worthy of clinical promotion and use.
NETL
NSTL
万方数据
